Empowered Funds LLC Has $946,000 Stake in IQVIA Holdings Inc. (NYSE:IQV)

Empowered Funds LLC raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 40.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,813 shares of the medical research company’s stock after buying an additional 1,376 shares during the period. Empowered Funds LLC’s holdings in IQVIA were worth $946,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new position in IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC increased its holdings in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. raised its position in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Finally, Concord Wealth Partners acquired a new stake in IQVIA in the third quarter valued at $57,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IQV. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Truist Financial reissued a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. cut their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Finally, UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $251.67.

Insiders Place Their Bets

In related news, Director John G. Danhakl purchased 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The shares were purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQV opened at $193.65 on Tuesday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a market cap of $35.15 billion, a P/E ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The business’s fifty day moving average is $200.41 and its 200-day moving average is $217.82.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.